CareFirst Opposes J&J's Bid To Revisit Stelara Antitrust Case

By Matthew Perlman · January 12, 2026, 10:34 PM EST

Insurer CareFirst urged a Virginia federal court to reject Johnson & Johnson's bid for reconsideration of a ruling that refused to toss antitrust and patent fraud claims over the immunosuppressive drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Carefirst of Maryland, Inc., et al. v. Johnson & Johnson, et al.

Case Number

Court

Virginia Eastern

Nature of Suit

Anti-Trust

Date Filed

December 07, 2023

Recent Articles By Matthew

January 09, 2026
Veterinary Group Says DOJ Accreditation Points Irrelevant
January 09, 2026
Judge Blocks Edwards' $945M Heart Valve Deal
December 15, 2025
DOJ Raises Accreditation Concerns In Vet School Case
December 04, 2025
Prolonged FTC Review Kills $615M Healthcare Staffing Deal
November 26, 2025
GTCR Drops FTC Constitutional Challenge Over Merger Case
November 24, 2025
FTC Abandons In-House GTCR Merger Case After Court Loss
November 21, 2025
PBMs Say Gov't Benefits From Drug Rebates FTC Condemns
November 20, 2025
FTC Withdraws In-House GTCR Merger Case
November 06, 2025
Edwards Defends $945M Heart Valve Deal From FTC Challenge
October 20, 2025
Justices Won't Review Merck's Immunity From Vaccine Claims